158 related articles for article (PubMed ID: 36547769)
1. Anticancer Properties of Saccharomyces boulardii Metabolite Against Colon Cancer Cells.
Pakbin B; Allahyari S; Dibazar SP; Peymani A; Haghverdi MK; Taherkhani K; Javadi M; Mahmoudi R
Probiotics Antimicrob Proteins; 2024 Feb; 16(1):224-232. PubMed ID: 36547769
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Properties of Probiotic Saccharomyces boulardii Supernatant on Human Breast Cancer Cells.
Pakbin B; Dibazar SP; Allahyari S; Javadi M; Amani Z; Farasat A; Darzi S
Probiotics Antimicrob Proteins; 2022 Dec; 14(6):1130-1138. PubMed ID: 35094296
[TBL] [Abstract][Full Text] [Related]
3. Effects of Probiotic
Pakbin B; Allahyari S; Dibazar SP; Zolghadr L; Chermahini NK; Brück WM; Brück TB; Mahmoudi R
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175663
[TBL] [Abstract][Full Text] [Related]
4. Antigenotoxicity and Cytotoxic Potentials of Cell-Free Supernatants Derived from Saccharomyces cerevisiae var. boulardii on HT-29 Human Colon Cancer Cell Lines.
Abbasi A; Rad AH; Maleki LA; Kafil HS; Baghbanzadeh A
Probiotics Antimicrob Proteins; 2023 Dec; 15(6):1583-1595. PubMed ID: 36588138
[TBL] [Abstract][Full Text] [Related]
5. Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory.
Jin Y; Yu S; Liu JJ; Yun EJ; Lee JW; Jin YS; Kim KH
Microb Cell Fact; 2021 Aug; 20(1):160. PubMed ID: 34407819
[TBL] [Abstract][Full Text] [Related]
6. Antioxidant properties and global metabolite screening of the probiotic yeast Saccharomyces cerevisiae var. boulardii.
Datta S; Timson DJ; Annapure US
J Sci Food Agric; 2017 Jul; 97(9):3039-3049. PubMed ID: 27868205
[TBL] [Abstract][Full Text] [Related]
7. Application of Saccharomyces cerevisiae var. boulardii in food processing: a review.
Lazo-Vélez MA; Serna-Saldívar SO; Rosales-Medina MF; Tinoco-Alvear M; Briones-García M
J Appl Microbiol; 2018 Oct; 125(4):943-951. PubMed ID: 29961970
[TBL] [Abstract][Full Text] [Related]
8. A Mutation in
Liu JJ; Zhang GC; Kong II; Yun EJ; Zheng JQ; Kweon DH; Jin YS
Appl Environ Microbiol; 2018 May; 84(10):. PubMed ID: 29523547
[TBL] [Abstract][Full Text] [Related]
9. New biomarkers underlying acetic acid tolerance in the probiotic yeast Saccharomyces cerevisiae var. boulardii.
Samakkarn W; Vandecruys P; Moreno MRF; Thevelein J; Ratanakhanokchai K; Soontorngun N
Appl Microbiol Biotechnol; 2024 Jan; 108(1):153. PubMed ID: 38240846
[TBL] [Abstract][Full Text] [Related]
10. Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast
Offei B; Vandecruys P; De Graeve S; Foulquié-Moreno MR; Thevelein JM
Genome Res; 2019 Sep; 29(9):1478-1494. PubMed ID: 31467028
[TBL] [Abstract][Full Text] [Related]
11. Unique Probiotic Properties and Bioactive Metabolites of Saccharomyces boulardii.
Fu J; Liu J; Wen X; Zhang G; Cai J; Qiao Z; An Z; Zheng J; Li L
Probiotics Antimicrob Proteins; 2023 Aug; 15(4):967-982. PubMed ID: 35608794
[TBL] [Abstract][Full Text] [Related]
12. Fungemia following Saccharomyces cerevisiae var. boulardii probiotic treatment in an elderly patient.
Landaburu MF; López Daneri GA; Relloso S; Zarlenga LJ; Vinante MA; Mujica MT
Rev Argent Microbiol; 2020; 52(1):27-30. PubMed ID: 31262611
[TBL] [Abstract][Full Text] [Related]
13. Probiotic
Pakbin B; Pishkhan Dibazar S; Allahyari S; Javadi M; Farasat A; Darzi S
Food Sci Nutr; 2021 Feb; 9(2):692-700. PubMed ID: 33598154
[TBL] [Abstract][Full Text] [Related]
14. Health-promoting properties of
Ansari F; Alian Samakkhah S; Bahadori A; Jafari SM; Ziaee M; Khodayari MT; Pourjafar H
Crit Rev Food Sci Nutr; 2023; 63(4):457-485. PubMed ID: 34254862
[No Abstract] [Full Text] [Related]
15. Alcoholic and non-alcoholic rosé wines made with Saccharomyces cerevisiae var. boulardii probiotic yeast.
Mulero-Cerezo J; Tuñón-Molina A; Cano-Vicent A; Pérez-Colomer L; Martí M; Serrano-Aroca Á
Arch Microbiol; 2023 Apr; 205(5):201. PubMed ID: 37081186
[TBL] [Abstract][Full Text] [Related]
16. Microbiome Engineering Using Probiotic Yeast:
Kim J; Atkinson C; Miller MJ; Kim KH; Jin YS
Microbiol Spectr; 2023 Aug; 11(4):e0078023. PubMed ID: 37436157
[TBL] [Abstract][Full Text] [Related]
17. The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407.
Murzyn A; Krasowska A; Augustyniak D; Majkowska-Skrobek G; Łukaszewicz M; Dziadkowiec D
FEMS Microbiol Lett; 2010 Sep; 310(1):17-23. PubMed ID: 20629753
[TBL] [Abstract][Full Text] [Related]
18. Saccharomyces boulardii alleviates ulcerative colitis carcinogenesis in mice by reducing TNF-α and IL-6 levels and functions and by rebalancing intestinal microbiota.
Wang C; Li W; Wang H; Ma Y; Zhao X; Zhang X; Yang H; Qian J; Li J
BMC Microbiol; 2019 Nov; 19(1):246. PubMed ID: 31694526
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Saccharomyces cerevisiae fungemia in hospitalised patients administered Saccharomyces boulardii probiotic.
Wombwell E; Bransteitter B; Gillen LR
Mycoses; 2021 Dec; 64(12):1521-1526. PubMed ID: 34585799
[TBL] [Abstract][Full Text] [Related]
20. The Probiotic Effects of the
Lee JE; Lee E
J Microbiol Biotechnol; 2022 Jul; 32(7):877-884. PubMed ID: 35791078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
